SSA Global, represented in SA by Labat Software Solutions, has released version 8.2 of its Business Planning and Control System (BPCS) ERP software.
"The new version of BPCS allows customers to optimise critical business processes while meeting or exceeding industry regulatory compliance requirements," says Mark Alexander, MD at Labat Software Solutions. "The enriched functionality of BPCS version 8.2 supports specific business needs and requirements for a variety of industry sectors, including automotive, consumer packaged goods, electronics, food and beverage, general manufacturing and pharmaceutical."
Some of these enhancements are e-Signature, Inventory Management, Lean Manufacturing and Seiban Manufacturing and Control.
e-Signature, aimed at the pharmaceutical industry, simplifies the authorisation process while ensuring regulatory compliance. Inventory Management offers dynamic weights and measures functionality so inventories can be viewed in dual units of measure. Lean Manufacturing provides more flexibility in scheduling and capacity loading while Seiban Manufacturing and Control enables organisations to link all customer project information together for better overall tracking, planning and control.
SSA Global is currently on the acquisition and merger trail, as well as growing the business and its products organically. This is aimed at enhancing the products, particularly BPCS.
The company`s extended ERP solutions will include corporate performance management; customer relationship management; financial management; human capital management; product lifecycle management; supply chain management; supplier relationship management and tools and technologies.
"Our acquisition strategy has two goals: to better serve our customers by acquiring product extensions that add industry functionality and enhanced value to our core ERP offering, and to expand market share by growing our existing ERP base," says Peter Prince, VP northern Europe at SSA Global.
The new version incorporates a new component called e-Signatures, specifically aimed at companies regulated by the US Food and Drug Administration.
Share
Editorial contacts